Novartis

BioNTech boosts COVID-19 vaccine capacity and aims to deliver 2 billion doses in 2021

This includes a recently acquired site in Marburg, Germany, which BioNTech acquired from Novartis in September 2020.

Biogen advances Spinraza study in SMA patients treated with Novartis’ Zolgensma

Novartis’ gene therapy Zolgensma. ... Novartis’ gene therapy was approved to treat SMA in patients aged two years and younger by the FDA in May 2019, with a price-tag of $2.1m per patient – making

Mesoblast’s stem cell therapy fails to meet primary endpoint in COVID-19 study

In a statement, Mesoblast said that it and Novartis “will both analyse these results to identify meaningful clinical outcomes that may guide decisions on the development programme for remestemcel-L in ... The results will also be a blow to Swiss pharma

After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

Collaborating with pharma companies, Oxford Biomedica uses its infrastructure to produce other companies’ licensed products, including Novartis’ Kymriah treatment (alongside other undisclosed CAR-T-related products).

Chaperone Leadership

While I’m prepared to accept a few shared basics, the idea that leading Novartis is the same as leading McDonalds seems preposterous.

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]